Published: 2021-07-30

Page: 50-65


Faculty of Nature and Life Sciences, University of Blida 1, Blida, Algeria.


High National Veterinary School (HNVS), Bab-Ezzouar, Algiers, Algeria and Institute of Veterinary Sciences, Laboratory of Biotechnologies related to Animal Reproduction, Algeria.


High National Veterinary School (HNVS), Bab-Ezzouar, Algiers, Algeria.


High National Veterinary School (HNVS), Bab-Ezzouar, Algiers, Algeria.


Institute of Veterinary Sciences, Laboratory of Biotechnologies related to Animal Reproduction, Algeria.

*Author to whom correspondence should be addressed.


Among gynecological tumors, malignant uterine tumor (MUT) is the sixth most common cancer in women and the 15th most common cancer overall. There were approximately 382069 new cases and 89929 deaths attributed to this type worldwide in 2018. It was therefore the second and fourth leading cause of death from gynecological cancer in women in recent years and is expected to increase by more than 50% globally by 2040. Mortality rates are lowest in Central Asia, South and most of Africa. Survivors of MUT may experience treatment-related issues, including infertility, early onset of menopause, sexual problems, and lower limb lymphedema. WHO builds its own database from national modeling incidence estimates, using incidence ratios with a sampling method that relies on the calculation of a weighted or simple average of the most popular local rates applied to the population of a few regions or by an approximate estimate based on data provided by health establishments in neighboring countries. While in Algeria, existing statistical and epidemiological data and updated information on the pathology are insufficient. The objective of this work is to highlight the importance and the situation of the MUT in this country and to describe the different recent aspects (etiology, diagnostic and treatment) related to the disease.

Keywords: Uterus, malignant tumor, woman, statistics, etiology, diagnostic, treatment, Algeria

How to Cite

AZZOUZ, M. Y., MIMOUNE, N., BAAZIZI, R., BENADJEL, O., & KAIDI, R. (2021). UTERINE TUMORS IN WOMEN: BIBLIOGRAPHIC DATA IN ALGERIA & AROUND THE WORLD. BIONATURE, 41(1), 50–65. Retrieved from https://globalpresshub.com/index.php/BN/article/view/1193


Download data is not yet available.


Taylan E, Oktay K. Fertility preservation in gynecologic cancers. Gynecologic Oncology; 2019.

DOI: 10.1016/j.ygyno.2019.09.012

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A Statistiques mondiales sur le cancer 2018: Estimations GLOBOCAN de l'incidence et de la mortalité dans le monde pour 36 cancers dans 185 pays. CA Cancer J Clin. 2018;68: 394–424.

IARC. Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. Continus update project expert report 2018. 2018;36.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Incidence du cancer et mortalité dans le monde: sources, méthodes et principaux modèles dans GLOBOCAN 2012. Int J Cancer. 2015 ;136:E359–86.

Torre LA, Farhad I, Siegel RL, Ward ME et Ahmedin J. Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomarkers. 2017;26(4): 444-457.

Zhang S, Gong TT, Liu FH et al. Fardeau mondial, régional et national du cancer de l'endomètre, 1990-2017: résultats de l'étude sur la charge mondiale de la maladie, 2017. Front Oncol. 2019;9:1440.

Publié le 19 décembre 2019

DOI: 10.3389 / fonc.2019.01440.

Hamdi Cherif M, Bidoli E, Birri S, Mahnane A, Zaidi Z, Boukharouba H, Moussaoui H, Kara L, Ayat A, Makhlou K, Bouchaibi I, Atoui, Virdone S, Serraino D. Cancer estimation of incidence and survival in Algeria 2014. J Cancer Res Ther. 2015;3:100- 104.

Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer; 2020.

Available:http://publications.iarc.fr/586. Licence: CC BY-NC-ND3.0 IGO.



INSP; 2019.


Gospodarowicz M, Benedet L, Hutter RV, Fleming I, Henson DE, Sobin LH. History and international developments in cancer staging. Cancer Prev Control. 1998;2(6):262-268.

Benedet JL. History of the annual report. Int J Gynecol Obstet; 2006; 95(Suppl. 1):S1–2.

Denoix PF, Schwartz D. General rules for classification of cancers and presentation of the therapeutic results. Mem Acad Chir. 1959;85:415–24.

Kottmeier HL. Annual report on the results of treatment in gynecological Cancer. FIGO; 1982.

Wittekind Ch, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH. TNM-Atlas. Guide illustré de la Classification TNM/pTNM des tumeurs malignes. 5th Ed. French version. Springer; 2005.

Carcopino X, Levêque J, Riethmuller D. Cancers Gynécologiques Pelviens. Elsevier Masson. 2013;352.

Suarez AA, Felix AS, Cohn DE. Bokhman Redux: Endometrial cancer “types” in the 21st century. Gynecologic Oncology. 2017 ;144(2): 243–249.

DOI: 10.1016/j.ygyno.2016.12.010.

Wilczyński M, Danielska J, Wilczyński J. An update of the classical Bokhman’s dualistic model of endometrial cancer. Menopausal Review. 2016;2:63–68.

DOI: 10.5114/pm.2016.61186

Just PA, Borghese B, Alexandre J. Classification des carcinomes de l’endomètre et de l’ovaire. Correspondances en Onco-Théranostic. 2015;IV - 4.

Kandoth C, Nikolaus Schultz, Andrew D. Cherniack, Rehan Akbani, Yuexin Liu, Hui Shen, A. Gordon Robertson, Itai Pashtan, Ronglai Shen, Christopher C. Benz, Christina Yau, Peter W. Laird, Li Ding, Wei Zhang, Gordon B. Mills, Raju Kucherlapati, Elaine R. Mardis, Douglas A. Levine. Cancer genome atlas research network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447): 67-73.

Blair AR, Casas CM. Gynecologic cancers. Prim Care Clin Office Pract 2009;36:115–130.

DOI: 10.1016/j.pop.2008.10.001

El-Harrak M. Education thérapeutique des patients atteints de cancer. Thèse de Doctorat en Pharmacie. Univ. Mohamed V, Faculté de médecine et de pharmacie, Rabat. Maroc; 2016.

Bats AS, Rossi L, Le Frere-Belda MA, Narjoz C, Cournou C, Gosset M, Ngo C, Delomenie M, Nos C, Blons H, Laurent-Puig P, Lecuru F. Lynch syndrome and endometrial cancer. Bull Cancer. 2017;104(12):1013-1021.

Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Diversité immunophéno-typique des adénocarcinomes de l'endomètre: implications pour le diagnostic différentiel. Contre Pathol. 2006;19(8):1091-100.

ACS. Global Cancer Facts & Figures 4th Edition. Atlanta: American Cancer Society; 2018.

Jain MG, Rohan TE, Howe GR, Miller AB. Une étude de cohorte sur les facteurs nutritionnels et le cancer de l'endomètre. Eur J Epidemiol. 2000; 16:899–905.

Collinet P, Poncelet P, Vinatier D. Cancerde l’endomètre. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 37. Hors-série 2. 2008;F57-F63.

Selbey JV, Friedman GD, Herrinton LJ. Pharmaceuticals other than hormones. In: Schottenfeld D, Fraumeni, JF eds, Cancer Epidemio-logy and Prevention, New York, Oxford University Press. 1996;489-501.

Pisani P, Parkin DM, Muñoz N, Ferlay J. Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev. 1997;6:387-400.

Baillet. Cours : Cancérologie. Chapitre 3. Université Pierre et Marie Curie. Faculté de médecine. Service de radiothérapie. Niveau DCEM3; 2015.

Belhaddad EH. La prise en charge du cancer de l’endomètre au CHU Med VI de Marrakech entre 2009 et 2017. Thèse N° 027. Faculté de médecine. Univ. Marrakech; 2019.

Goodman A. Endometrial cancer: Screening, diagnosis, and surgical staging. In Muggia F, Santin AD, Oliva E (2018). Uterine Cancer: Screening, Diagnosis, and Treatment. Springer 2018;13-24.

CoPath. Anatomie-pathologique. Polycopie. Collège Français des Pathologistes. Chapitres 1, 7, 8, 9, 10 et 11; 2012.

Pautier P, Haie-Meder C. Le cancer de l’endomètre. Fondation ARC pour la recherche sur le cancer. 2013;29.

Melissa AM, Daniel WC. Molecular Pathogenesis of Endometrial and Ovarian Cancer, Cancer Biomark. 2010;9(0).

Soslow RA, Oliva E. Uterine Cancer: Pathology. In Muggia et Oliva (2009). Uterine Cancer Screening, Diagnosis, and Treatment, Humana Press, Springer Science+Business Media. New York; 2009.

Allen DC. Histopathology reporting. Guidelines for surgical cancer, 2nd Ed, Springer. 2006;239-293.

Ellenson LH. Endometrial Carcinoma- Molecular genetic aspects in Giordano et al. Molecular Pathology of Gynecologic Cancer. Humana Press Inc. Totowa, New Jersey 2007;99-108.

Buza N. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand. Arch Pathol Lab Med; 2020.

DOI: 10.5858/arpa.2020-0207-ra.

Sutton C. Hystérectomie: une perspective historique. Ballon. Clin. Obstet. Gynaecol. 1997;11:1–22.

Deffieux X, et al. Hystérectomie pour pathologie bénigne: recommanda-tions pour la pratique clinique. J Gynecol Obstet Biol Reprod. 2015; 44(10):1219-1227.

Van der Meij E, Emanuel MH. Hystérectomie pour saignement menstruel abondant. 2016;12(1):63-69.

Agostini A, Bretelle F, Cravello L. Hystérectomie vaginale chez les femmes nullipares sans prolapsus: une étude comparative prospective. BJOG. 2003;110:515–518.

Balogun O, Lymberis S, Schiff PB. Early-stage endometrial cancer: radiation-Less may be more. Muggia F, Santin AD, Oliva E (2018). Uterine Cancer: Screening, Diagnosis, and Treatment. Springer. 2018;183-200.

Duska LR. Primary hormonal therapy of endometrial cancer. In Muggia F, Santin AD, Oliva E (2018). Uterine Cancer: Screening, Diagnosis, and Treatment. Springer. 2018;151-169.

Musa F. Treatment of advanced and recurrent carcinoma: Chemotherapy. In Muggia F, Santin AD, Oliva E (2018). Uterine Cancer: Screening, Diagnosis, and Treatment. Springer. 2018;223-234.

Ling Shen, Liangli Hong, Songxia Zhou, Ruiqin Mai. Mutational landscape implicates epithelial-mesenchymal transition gene TGF-β2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma. Int J Clin Exp Patho. 2019;12(3):996-1002.

Pant A, Lee II, Lu Z, et al. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One. 2012;7(7):e41593.

Konecny GE, Santos L, Winterhoff B, et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009;100:89- 95.

Rita Luz, Joana FerreiraMara Rocha, Ana Félix. Carcinossarcoma Uterino: Características ClinicoPatológicas e Fatores de Prognóstico. Acta médica portuguesa. 2016;29(10):621.

Black JD, Roque DM, Gold LI, Santin AD. Future directions and new targets in endometrial cancer. In Muggia F, Santin AD, Oliva E (2018). Uterine Cancer: Screening, Diagnosis, and Treatment. Springer. 2018;259-271.

Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83(2): 388–93.

Park JY, Seong SJ, Kim TJ, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol. 2013;121(1):136–42.

Christina A. Fleming, Heneghan HM, O'BrienRuth D, Prichard S. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy: Risk of endometrial malignancy and endometrial surveillance in extended tamoxifen therapy. British Journal of Surgery. 2018;105(Suppl).